A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (NCT04714073), a na phase 1 study. The primary outcome is Area Under the Concentration-time Curve of BI 706321 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).

2. Clinical Question

The question concerns pharmacokinetics: the concentration of BI 706321 in plasma over time, and the total exposure represented by the area under its concentration-time curve. Itraconazole is included as a concomitant drug in the study question, not as a treatment assigned through a randomized comparison. The aim described in the record is to investigate BI 706321 given alone or in combination with itraconazole.

This is a study in healthy male subjects, not a trial of clinical benefit in people with a disease. Its primary endpoint addresses drug exposure, not symptom change, disease control, or a patient-important clinical outcome. The registry record does not report a numerical exposure estimate for either regimen, an estimated contrast between regimens, or a confidence interval. Consequently, the direction and precision of any difference in exposure cannot be described from the posted results.

3. Trial Design

The registry record describes a Phase 1, open-label study with a two-period fixed-sequence design and a single-group model. It records 14 participants enrolled and a completed status. The study began on 2021-02-11, with primary completion on 2021-04-30. The population is described as healthy, and the title specifies healthy male subjects.

The fixed-sequence description matters for interpretation. The study was not randomized, and allocation is recorded as NA. Participants proceeded through treatment periods in a prescribed order rather than being assigned to separate, concurrent randomized groups. The arm description identifies BI 706321 alone as the reference treatment in period 1 and BI 706321 with itraconazole as the test treatment in period 2. It also lists itraconazole alone in period 2. The record explicitly cautions that the arms are not a like-for-like control comparison.

For the reference treatment, the record describes a single oral dose of one film-coated tablet containing 2 mg BI 706321, taken with 240 mL of water after an overnight fast of at least 10 hours. For period 2, the description says that 200 mg itraconazole was administered, but does not complete the dosing details. Specific timing, duration, and additional instructions for period 2 are not reported in the registry record.

Masking is recorded as none, consistent with the open-label designation. No placebo or blinding procedure is described. A detailed protocol, washout interval, adherence procedures, and the rationale for the period sequence are not reported in the registry record. The posted description therefore supports a basic account of the design and treatments, but not a reconstruction of all operational details.

The study is intended to characterize pharmacokinetics rather than compare clinical outcomes between independently randomized groups. Because treatment conditions are encountered in a fixed order, any interpretation of a within-participant regimen contrast must recognize the sequence and period structure. The record does not report enough detail to assess how possible period or sequence effects were addressed analytically.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.

Period 1 (+Washout Period)

Period 2

Analysis population for the primary outcome, as defined in the registry: Pharmacokinetic parameter analysis set (PKS): All subjects in the treated set who provided at least 1 Pharmacokinetic (PK) endpoint that was defined as primary or secondary and was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Treated set (TS): The TS included all subjects who were treated with at least 1 dose of study drug.

6. Primary Endpoint

The registry lists the primary outcome as Area Under the Concentration-time Curve of BI 706321 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞), measured over Within 3 hours (h) (1h for period 2) before and at 0.5h to 190h after BI 706321 administration in each period. Further at 214h to 550h after BI 706321 administration in period 2..

The primary endpoint is the area under the plasma concentration-time curve for BI 706321, extrapolated from time zero to infinity, denoted AUC0-∞ in the endpoint description. The unit is hours multiplied by nanomoles per liter. The area under a concentration-time curve represents drug exposure over the measurement interval: it combines information about measured concentrations and how long those concentrations persist.

Extrapolation to infinity extends the exposure estimate beyond the last measured concentration, using the terminal part of the concentration-time profile. This can provide an overall exposure measure when sampling does not continue until drug concentrations reach zero. The quality of that estimate depends on the observed concentration profile and the extent to which the terminal phase can be characterized. The registry record does not report the numerical endpoint values or details of the extrapolation calculation.

Exposure is useful in a pharmacokinetic study because it allows comparison of the amount of drug in the body over time under different dosing conditions. In this study, the stated question is whether exposure to BI 706321 differs when it is taken with itraconazole compared with BI 706321 alone. AUC is a pharmacokinetic measure; by itself, it does not establish a clinical benefit or harm.

The registry specifies geometric mean as the summary measure and standard error as the accompanying dispersion measure. The stated assessment period includes measurements before and after BI 706321 administration in each period. Numerical geometric means, standard errors, and a treatment contrast are not reported in the registry record, so the magnitude and precision of the primary endpoint cannot be evaluated from these entries.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The method described by the registry begins with serial measurement of BI 706321 concentrations in plasma. The primary endpoint, AUC0-∞, is an integrated measure of exposure over time. In general, integration summarizes the concentration curve rather than relying on a single concentration at one time point. Extrapolation beyond the last quantifiable observation is part of the endpoint definition, but the registry record does not describe the calculation method or report what proportion of the estimate came from extrapolation.

What does a geometric mean communicate?

The endpoint summary is identified as a geometric mean. In general, a geometric mean summarizes values on a multiplicative scale and is often used for pharmacokinetic measures that are positive and may be right-skewed. It differs from an arithmetic mean, which summarizes values on an additive scale. The choice can affect how an average is interpreted, especially when individual values vary substantially. The registry record names the geometric mean but does not provide the values or describe any transformation or model used to estimate it.

What does standard error describe?

The listed dispersion measure is standard error. In general, standard error describes the estimated sampling uncertainty of a statistic, such as a mean; it is not a direct description of the spread of individual participant measurements. A standard deviation is commonly used to describe participant-level variability, whereas a standard error concerns the precision of an estimated summary. Since the record does not post a standard error value or a confidence interval, the precision of the primary estimate cannot be assessed.

Why does the treatment sequence matter?

A fixed-sequence, two-period design means the conditions are encountered in a set order. If the same participants contribute measurements under more than one condition, the comparison can use within-participant information, which may account for stable differences between participants. However, period effects, changes over time, carryover, and incomplete measurements may matter. These are general considerations for repeated-period studies; the registry record does not report whether or how they were assessed, nor does it describe a washout interval.

Because this is not a randomized comparison, the treatment labels do not represent independently randomized groups. The record explicitly warns that the arms are not a like-for-like control comparison. This does not by itself invalidate a pharmacokinetic design, but it does mean that the comparison should be interpreted according to its sequence and analysis rather than as though treatment assignment had been randomized. The analysis plan and any adjustment for period or sequence are not reported in the registry record.

Why might concentration data require specialized analysis?

Pharmacokinetic measurements can vary over time and between participants. In general, concentration profiles may be skewed, and measurements near or below quantification limits can affect summaries. When data show more variability than a simple model assumes, over-dispersion can make conventional standard errors too small and tests too optimistic. This is a general statistical issue, not a documented feature of this study. The record does not describe the distribution of measurements, any model diagnostics, or methods for handling measurements below quantification limits.

For a comparison of exposure measures, analysts may report a treatment contrast and an interval expressing uncertainty. A confidence interval is generally informative because it shows both the estimated contrast and the range of values reasonably compatible with the analysis. A p-value, if used, addresses compatibility with a specified null hypothesis under model assumptions; it does not measure the size or clinical importance of an effect. Neither a contrast, confidence interval, nor p-value for the primary endpoint is reported in the registry record.

The registry defines the pharmacokinetic analysis set as treated participants who provided at least one eligible primary or secondary pharmacokinetic endpoint and were not excluded because of a relevant protocol deviation or pharmacokinetic non-evaluability. This definition indicates that analysis eligibility depends on usable pharmacokinetic data and specified exclusions. The record does not state how many participants entered that analysis set, how many contributed to each endpoint, or how missing measurements were handled.

Overall, the design and endpoint labels identify the broad statistical framework, but they do not disclose a complete analysis method. The model, exact comparison scale, covariates, assumptions, treatment of missing values, and interval-estimation procedure are not reported in the registry record. Those omissions prevent a reader from independently assessing the reported primary result, and no numerical primary result is posted to evaluate.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists three outcome measures and three analyses, but it does not report a statistical analysis plan or explain how the outcomes and analyses relate to one another. A multiplicity adjustment, testing hierarchy, or prespecified approach to controlling false-positive findings is not reported in the registry record. This matters because drawing conclusions from several endpoints or analyses can increase the chance of a seemingly notable result arising by chance. Without the planned testing strategy, the role of any individual analysis cannot be determined.

The record defines a pharmacokinetic analysis set: treated participants with at least one eligible primary or secondary pharmacokinetic endpoint, excluding participants with relevant protocol deviations or pharmacokinetic non-evaluability. The number of participants included in that set, and the number contributing to each endpoint, are not reported in the registry record. The record also does not describe a separate intention-to-treat or per-protocol analysis population.

Missing-data procedures are not reported in the registry record. It is not stated how missing concentration measurements, incomplete profiles, or unavailable endpoint estimates were handled. The record does not describe imputation, sensitivity analyses, or rules for incomplete follow-up. These details are important because pharmacokinetic exposure estimates depend on the availability and interpretability of measurements over time.

Sample-size justification, assumptions used in planning, interim analyses, and the statistical analysis plan are not reported in the registry record. No inferential conclusion should be attributed to a particular testing or missing-data procedure unless it is documented. The posted record supports the analysis-set definition, but leaves the broader multiplicity and missing-data methods unspecified.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The serious-adverse-event figures list 14 participants at risk in each treatment category and zero participants affected by a serious adverse event in each category. The overall category also records zero serious adverse events among 14 participants. Deaths are recorded as zero throughout. These are the posted counts for this study; they are not evidence that serious events are impossible or that risk is absent.

The record also lists participants affected by other adverse events: 5 for BI 706321 in period 1, 3 for itraconazole alone in period 2, and 5 for BI 706321 plus itraconazole in period 2. The category labelled total BI 706321 records 8, while the overall total records 10. Because the study uses periods and the same participant group may contribute to more than one category, these counts should not be added as though they were independent sets of people. The record does not provide event descriptions in the posted summary, attribution, severity breakdowns, or timing by event.

Zero serious events in a study of this size is a descriptive finding, not a precise estimate of uncommon risks. The safety figures also do not establish whether an event was caused by BI 706321, itraconazole, their combination, or another factor. They should be read as counts recorded under the registry's categories, not as a randomized safety comparison.

12. What the Result Does, and Does Not, Mean

This study is relevant to a specific statistical question: whether BI 706321 exposure, measured by plasma AUC0-∞, differs between administration alone and administration with itraconazole. The registry identifies the endpoint and a fixed-sequence design, but does not report the primary pharmacokinetic estimates. As a result, the posted information does not establish the direction or magnitude of an exposure difference, nor how precisely such a difference was estimated.

The study's pharmacokinetic focus also defines what the endpoint can say. AUC is a measure of drug exposure, not a direct measure of clinical benefit, symptom response, or disease outcome. The participants are described as healthy men, so the record does not present evidence about effects in a patient population. No medical recommendation or conclusion about treatment use follows from the endpoint definition or the available counts.

The posted safety counts indicate no serious adverse events and no deaths in the listed categories, with other adverse events recorded. These observations describe what was recorded in the study and do not demonstrate that the treatments have identical safety profiles or rule out uncommon events. The categories also overlap in a sequential design, so group counts should not be interpreted as independent randomized comparisons.

The record does not report the statistical analysis plan, confidence intervals, primary endpoint values, sample-size justification, or missing-data methods. Consequently, it is not possible to assess the primary result's precision, the robustness of its analysis, or the treatment of incomplete profiles. The study's completed status indicates that the trial is recorded as completed; it does not provide the missing numerical results.

The most defensible reading is therefore narrow: the registry documents a Phase 1 pharmacokinetic study of BI 706321 alone and with itraconazole in healthy men, defines AUC0-∞ as the primary measure, and posts descriptive safety counts. It does not report the numerical primary comparison needed to quantify the pharmacokinetic finding.

13. Why This Trial Matters Statistically

This study illustrates why a clearly named endpoint is not enough to interpret a clinical-trial record. AUC0-∞ gives a meaningful pharmacokinetic target: cumulative exposure to BI 706321 over time, including an extrapolated component. But without the estimated values, treatment contrast, and uncertainty, the endpoint definition cannot answer how exposure differed between regimens.

The design also matters statistically. The registry describes an open-label, two-period fixed sequence and explicitly cautions that its arms are not a like-for-like control comparison. That distinction helps prevent readers from treating sequential conditions as randomized parallel groups. A valid interpretation depends on understanding which participants contributed measurements under each condition and how the analysis addressed sequence and period structure. Those details are not reported in the registry record.

The record further demonstrates the difference between a safety count and a safety conclusion. It posts zero serious adverse events in the listed categories and records other adverse events, but those figures alone do not estimate rare risks or establish causality. The sequence and overlap in participant categories also matter when reading totals.

For biostatisticians and clinical researchers, the central lesson is that design, endpoint, analysis population, uncertainty, and missing-data handling must be considered together. Here, some design and endpoint definitions are available, while the numeric primary results and detailed analysis procedures are not reported in the registry record. That gap limits what can be concluded, regardless of the study's completed status.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The key limitation for interpretation is that the registry record does not report numerical results for the primary pharmacokinetic endpoint. It provides no AUC0-∞ estimates, treatment contrast, confidence interval, or p-value. The primary question therefore cannot be answered quantitatively from the posted record, and its precision cannot be judged.

The study is described as an open-label, two-period fixed-sequence, single-group study with no random allocation. The record itself warns that the arms are not a like-for-like control comparison. The sequence may make treatment and period inseparable unless the analysis addresses period-related effects; the methods used to handle this are not reported in the registry record. Details such as a washout interval and the complete period 2 dosing schedule are also not reported.

The registry defines a pharmacokinetic analysis set but does not report its size or the number of participants contributing to each endpoint. Exclusions for relevant protocol deviations or pharmacokinetic non-evaluability are part of the definition, but the actual exclusions and their reasons are not reported. Missing-measurement procedures and sensitivity analyses are not reported in the registry record.

The record does not report a sample-size justification, a statistical analysis plan, multiplicity procedures, or interim analyses. It also provides limited safety detail beyond counts: event terms, attribution, and severity information are not included in the posted summary. With enrollment of 14, the descriptive safety counts cannot establish the frequency of uncommon events. These limitations are specific to the information recorded and prevent a fuller assessment of the primary estimate, its analysis, and the safety profile.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood — NCT04714073.
• Registry record last updated 2025-09-12; status last verified 2025-09.
• Results first posted 2025-09-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT04714073 is a completed Phase 1, open-label study in healthy men with a two-period fixed-sequence design. The registry records 14 participants enrolled. Its stated purpose is to investigate BI 706321 pharmacokinetics when administered alone or with itraconazole.

The primary endpoint is plasma AUC0-∞ for BI 706321, summarized as a geometric mean with standard error. BI 706321 alone is identified as the reference treatment, and BI 706321 with itraconazole as the test treatment. The primary numerical result and its uncertainty are not reported in the registry record. The record also lists no serious adverse events or deaths in the reported categories, with other adverse events recorded.

The analysis-set definition is available, but the analysis plan, sample-size justification, multiplicity procedures, and missing-data methods are not reported in the registry record. The posted information supports a description of the design and endpoint, but not a quantitative conclusion about the pharmacokinetic comparison.